158 related articles for article (PubMed ID: 33143428)
1. Effectiveness of the Iron Chelator CN128 in Mitigating the Formation of Dopamine Oxidation Products Associated with the Progression of Parkinson's Disease.
Sun Y; Pham AN; Hider RC; Zheng H; Waite TD
ACS Chem Neurosci; 2020 Nov; 11(21):3646-3657. PubMed ID: 33143428
[TBL] [Abstract][Full Text] [Related]
2. Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
Sun Y; Pham AN; Waite TD
ACS Chem Neurosci; 2018 May; 9(5):1118-1127. PubMed ID: 29381045
[TBL] [Abstract][Full Text] [Related]
3. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
4. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
[TBL] [Abstract][Full Text] [Related]
5. CN128: A New Orally Active Hydroxypyridinone Iron Chelator.
Chen W; Yuan X; Li Z; Lu Z; Kong S; Jiang H; Du H; Pan X; Nandi M; Kong X; Brown K; Liu Z; Zhang G; Hider RC; Yu Y
J Med Chem; 2020 Apr; 63(8):4215-4226. PubMed ID: 32208614
[TBL] [Abstract][Full Text] [Related]
6. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the interplay between Fe(II), Fe(III), and dopamine with relevance to iron solubilization and reactive oxygen species generation by catecholamines.
Sun Y; Pham AN; Waite TD
J Neurochem; 2016 Jun; 137(6):955-68. PubMed ID: 26991725
[TBL] [Abstract][Full Text] [Related]
8. Role of dopamine in the pathophysiology of Parkinson's disease.
Zhou ZD; Yi LX; Wang DQ; Lim TM; Tan EK
Transl Neurodegener; 2023 Sep; 12(1):44. PubMed ID: 37718439
[TBL] [Abstract][Full Text] [Related]
9. Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: implications for iron-related dopaminergic neuron degeneration.
Zhou ZD; Lan YH; Tan EK; Lim TM
Free Radic Biol Med; 2010 Dec; 49(12):1856-71. PubMed ID: 20854902
[TBL] [Abstract][Full Text] [Related]
10. To what extent may aminochrome increase the vulnerability of dopaminergic neurons in the context of Parkinson's disease.
Chagraoui A; Anouar Y; De Deurwaerdere P; Arias HR
Int J Biochem Cell Biol; 2024 Mar; 168():106528. PubMed ID: 38246261
[TBL] [Abstract][Full Text] [Related]
11. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity.
Shen XM; Dryhurst G
Chem Res Toxicol; 1998 Jul; 11(7):824-37. PubMed ID: 9671546
[TBL] [Abstract][Full Text] [Related]
12. Protective and toxic roles of dopamine in Parkinson's disease.
Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
[TBL] [Abstract][Full Text] [Related]
13. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.
Ben-Shachar D; Eshel G; Finberg JP; Youdim MB
J Neurochem; 1991 Apr; 56(4):1441-4. PubMed ID: 1900527
[TBL] [Abstract][Full Text] [Related]
14. The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
Zhou ZD; Xie SP; Saw WT; Ho PGH; Wang H; Lei Z; Yi Z; Tan EK
Cells; 2019 Aug; 8(8):. PubMed ID: 31426448
[No Abstract] [Full Text] [Related]
15. The effect of vitamin C and iron on dopamine-mediated free radical generation: implications to Parkinson's disease.
Sun Y; Pham AN; Waite TD
Dalton Trans; 2018 Mar; 47(12):4059-4069. PubMed ID: 29406547
[TBL] [Abstract][Full Text] [Related]
16. Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification.
Bjørklund G; Hofer T; Nurchi VM; Aaseth J
J Inorg Biochem; 2019 Oct; 199():110717. PubMed ID: 31369907
[TBL] [Abstract][Full Text] [Related]
17. Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Devos D; Moreau C; Devedjian JC; Kluza J; Petrault M; Laloux C; Jonneaux A; Ryckewaert G; Garçon G; Rouaix N; Duhamel A; Jissendi P; Dujardin K; Auger F; Ravasi L; Hopes L; Grolez G; Firdaus W; Sablonnière B; Strubi-Vuillaume I; Zahr N; Destée A; Corvol JC; Pöltl D; Leist M; Rose C; Defebvre L; Marchetti P; Cabantchik ZI; Bordet R
Antioxid Redox Signal; 2014 Jul; 21(2):195-210. PubMed ID: 24251381
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease.
Khan FH; Sen T; Maiti AK; Jana S; Chatterjee U; Chakrabarti S
Biochim Biophys Acta; 2005 Jun; 1741(1-2):65-74. PubMed ID: 15925494
[TBL] [Abstract][Full Text] [Related]
19. Effect of release of dopamine on iron transformations and reactive oxygen species (ROS) generation under conditions typical of coastal waters.
Sun Y; Pham AN; Waite TD
Environ Sci Process Impacts; 2018 Jan; 20(1):232-244. PubMed ID: 29265130
[TBL] [Abstract][Full Text] [Related]
20. Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases.
Monzani E; Nicolis S; Dell'Acqua S; Capucciati A; Bacchella C; Zucca FA; Mosharov EV; Sulzer D; Zecca L; Casella L
Angew Chem Int Ed Engl; 2019 May; 58(20):6512-6527. PubMed ID: 30536578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
